NKTX

Nkarta, Inc.
—

Company Information

Company Name
Nkarta, Inc.
CIK
CIK0001787400
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
NKTX: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
NKTX

SEC filing data through

Insider Sentiment

Last purchase
2024-03-27
Last sale
2026-06-18
Shares purchased (TTM)
0
Shares sold (TTM)
35,261
Buy ratio (TTM)0.0%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
57,523,202
Shares outstanding
74,494,855
Ownership
77.22%
-0.44% Y/Y

Earnings Market Reaction

Filing date
2026-08-10
Price on filing date
—
1-month reaction
18.70%
3-month reaction
…
Drift continued7/11 (64%)
Faded / reversed4/11 (36%)

Balance Sheet

Values in millions ($)
Line item2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets Current
Cash And Cash Equivalents At Carrying Value25274060535328571202503138
Short Term Investments158203237222236213239226204187217237
Prepaid Expense And Other Assets Current556776677556
Assets Current188236283289297272273290332443253281
Long Term Investments5834163142841101199910--
Restricted Cash Noncurrent333333333333
Property Plant And Equipment Net576467687073757678797978
Operating Lease Right Of Use Asset313434343536363939394041
Other Assets Noncurrent122225454444
Assets338372404427448471501532554577379406
Liabilities Current
Accounts Payable Current422121124344
Operating Lease Liability Current777676676666
Accrued Liabilities Current121013111111121412131415
Liabilities Current241822191919192221222326
Operating Lease Liability Noncurrent666870707273747980818283
Other Liabilities Noncurrent0000000-----
Liabilities90869289919293101101103106109
Stockholders Equity
Common Stock Value000000000000
Additional Paid In Capital Common Stock965962960958956954952947943939709705
Accumulated Other Comprehensive Income Loss Net Of Tax-0-0010112-0-00-0
Retained Earnings Accumulated Deficit-717-676-648-621-599-576-544-518-490-465-435-408
Stockholders Equity248286312338358379408431453474273297
Liabilities And Stockholders Equity338372404427448471501532554577379406
Preferred Stock Par Or Stated Value Per Share--0.00---0.00---0.00-
Preferred Stock Shares Authorized--54---54---54-
Preferred Stock Shares Issued--0---0---0-
Preferred Stock Shares Outstanding--0---0---0-
Common Stock Par Or Stated Value Per Share--0.00---0.00-0.00-0.00-
Common Stock Shares Authorized--200---200-100-100-
Common Stock Shares Issued--71---71---49-
Shares Outstanding--71---71---49-

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

Nkarta, Inc. (NKTX) — SEC Financial Statements & Analysis

Nkarta, Inc. (NKTX) is a pharmaceutical preparations company, incorporated in DE. Nkarta, Inc. trades on Nasdaq as: NKTX. Nkarta, Inc. (NKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Nkarta, Inc. carries a market cap of $210.82M, a P/E ratio of -1.80x, a P/B ratio of 0.85x, an enterprise value of $185.86M, and an EV/EBITDA multiple of -1.52x. On profitability, it posts a Return on Equity (ROE) of -38.76%, a Return on Assets (ROA) of -29.86%, and a Return on Invested Capital (ROIC) of -50.45%. Per share, it reports EPS of $-1.57, diluted EPS of $-1.57, free cash flow per share of $-1.26, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 7.40% year-over-year and EPS growth of 6.66% year-over-year. On the balance sheet, it maintains a current ratio of 7.98x, a quick ratio of 7.76x, working capital of $164.48M, a debt-to-equity ratio of 0.36x, a debt ratio of 0.27, free cash flow of $-93.92M (TTM), and net debt of $-24.96M. Figures sourced from SEC EDGAR.

Market Cap
$210.82M
P/E TTM
-1.80x
EPS TTM
$-1.57
P/B TTM
0.85x
ROE TTM
-38.76%
ROA TTM
-29.86%
Debt To Equity
0.36x
Free Cash Flow TTM
$-93.92M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Nkarta, Inc. in?

Nkarta, Inc. (NKTX) operates in the Pharmaceutical Preparations industry.

What exchange does NKTX trade on?

Nkarta, Inc. (NKTX) trades on the Nasdaq.

Where is Nkarta, Inc. incorporated?

Nkarta, Inc. is incorporated in DE.

When was Nkarta, Inc. (NKTX)'s most recent SEC filing?

Nkarta, Inc. (NKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.

What is NKTX's market cap?

Nkarta, Inc. (NKTX) has a market capitalization of $210.82M as of 2026-06-30.

What is NKTX's EPS (earnings per share)?

Nkarta, Inc. (NKTX)'s trailing twelve month EPS is $-1.57 as of 2026-06-30.

What is NKTX's ROE (return on equity)?

Nkarta, Inc. (NKTX)'s trailing twelve month Return on Equity (ROE) is -38.76% as of 2026-06-30.

What is NKTX's ROA (return on assets)?

Nkarta, Inc. (NKTX)'s trailing twelve month Return on Assets (ROA) is -29.86% as of 2026-06-30.

What is NKTX's ROIC (return on invested capital)?

Nkarta, Inc. (NKTX)'s trailing twelve month Return on Invested Capital (ROIC) is -50.45% as of 2026-06-30.

What is NKTX's EV/EBITDA?

Nkarta, Inc. (NKTX)'s trailing twelve month EV/EBITDA is -1.52x as of 2026-06-30.

Wall Street's data.
Main Street's price.